The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

European Medicines Agency ◽

Medicinal Products ◽

Scientific Assessment ◽

Large Cell Lymphoma ◽

Human Use

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2015.03.011 ◽

2015 ◽

Vol 95 (3) ◽

pp. 359-369 ◽

Cited By ~ 19

Author(s):

P.L. Zinzani ◽

S. Sasse ◽

J. Radford ◽

O. Shonukan ◽

V. Bonthapally

Keyword(s):

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

Program Review ◽

Review Of The Literature ◽

Large Cell Lymphoma ◽

Refractory Hodgkin Lymphoma

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Expert Review of Hematology ◽

10.1080/17474086.2021.1942831 ◽

2021 ◽

Author(s):

Yuqin Song ◽

Ye Guo ◽

Huiqiang Huang ◽

Wei Li ◽

Xiaoyan Ke ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

Chinese Patients ◽

Classical Hodgkin Lymphoma ◽

Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study

Leukemia & Lymphoma ◽

10.1080/10428194.2019.1654100 ◽

2019 ◽

Vol 61 (1) ◽

pp. 176-180 ◽

Cited By ~ 2

Author(s):

Noriko Fukuhara ◽

Go Yamamoto ◽

Hideki Tsujimura ◽

Takaaki Chou ◽

Hirohiko Shibayama ◽

...

Keyword(s):

Retrospective Study ◽

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

Classical Hodgkin Lymphoma ◽

Long‐Term Responders After Brentuximab Vedotin: Single‐Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

The Oncologist ◽

10.1634/theoncologist.2016-0112 ◽

2016 ◽

Vol 21 (12) ◽

pp. 1436-1441 ◽

Cited By ~ 11

Author(s):

Letizia Gandolfi ◽

Cinzia Pellegrini ◽

Beatrice Casadei ◽

Vittorio Stefoni ◽

Alessandro Broccoli ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

Single Center ◽

Single Center Experience ◽

Large Cell Lymphoma ◽

Refractory Hodgkin Lymphoma

Brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: a review of clinical experience and future directions

International Journal of Hematologic Oncology ◽

10.2217/ijh.13.59 ◽

2013 ◽

Vol 2 (6) ◽

pp. 455-465 ◽

Cited By ~ 1

Author(s):

Yehuda E Deutsch ◽

Izidore S Lossos ◽

Joseph D Rosenblatt

Keyword(s):

Hodgkin Lymphoma ◽

Clinical Experience ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

Future Directions ◽

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Nature Biotechnology ◽

10.1038/nbt.2289 ◽

2012 ◽

Vol 30 (7) ◽

pp. 631-637 ◽

Cited By ~ 474

Author(s):

Peter D Senter ◽

Eric L Sievers

Keyword(s):

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

Brentuximab vedotin in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma

Community Oncology ◽

10.1016/j.cmonc.2011.12.007 ◽

2012 ◽

Vol 9 (1) ◽

pp. 5-7

Author(s):

Jame Abraham

Keyword(s):

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

OncoTargets and Therapy ◽

10.2147/ott.s39107 ◽

2013 ◽

pp. 45 ◽

Cited By ~ 4

Author(s):

Jonathan Fromm ◽

Lorinda Soma ◽

Xueyan Chen

Keyword(s):

Targeted Therapy ◽

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Large Cell ◽

Brentuximab Vedotin ◽

A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL)

Hematological Oncology ◽

10.1002/hon.2438_111 ◽

2017 ◽

Vol 35 ◽

pp. 248-249 ◽

Cited By ~ 7

Author(s):

F. Locatelli ◽

C. Mauz-Koerholz ◽

K. Neville ◽

A. Llort ◽

A. Beishuizen ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Pediatric Patients ◽

Cell Lymphoma ◽

Phase 1 ◽

Large Cell ◽

Brentuximab Vedotin ◽

Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Annals of Pharmacotherapy ◽

10.1345/aph.1q680 ◽

2012 ◽

Vol 46 (3) ◽

pp. 377-383 ◽

Cited By ~ 24

Author(s):

Stephanie S Minich

Keyword(s):

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Large Cell ◽

New Age ◽

Brentuximab Vedotin ◽